After a multidisciplinary review by our oncology team, it was determined that the malignancy might be susceptible to BRAF and MEK inhibition, as well as their combination with anti-EGFR antibody therapy, following the same rationale as BRAF mutation-positive colorectal cancer. The gene discussed is MAP2K7; the disease is colorectal cancer.